Health Canada has announced that Trimel Pharmaceuticals is compliant with Good Manufacturing Practices (GMP) for the manufacture of clinical supplies.
Subscribe to our email newsletter
Trimel intends to use the Dunwin facility to manufacture clinical supplies for its CompleoTRT and TBS-2 (Anorgasmia) products.
The company intends to use Dunwin facility to even the balance its pipeline including those compounds under development with the TriVair pulmonary delivery system.
Trimel has demonstrated to Health Canada that the activities it conducts at its Dunwin facility conform to the Food and Drugs Act and its associated regulations.
Trimel chairman and CEO Bruce Brydon said that the company has now achieved first step toward the commercial supply of its products with the strictest adherence to quality.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.